Monoclonal Antibodies Therapeutic Landscape Explored by CBR Pharma Insights in In-demand Report Available at MarketPublishers.com14 Nov 2017 • by Natalie Aster
LONDON – Since the mid-1970s, and a substantial number of monoclonal antibody (mAbs) products have come into the market. Still, the majority remain in early-stage development, demonstrating delays and holdbacks in the development of promising products. In spite of this, mAbs are the biggest and most rapidly evolving segment of the biopharmaceutical market space, and capture nearly half of the overall revenue generated by this area every year.
The pipeline is very active, with 2,836 mAbs presently in development. The majority of them are at an early development stage, with 76% at the stage of discovery or preclinical research. In addition, there are 85 phase III development mAb programmes, with 22 at stage I, capturing less than 4% of the overall mAb pipeline.
Among the products marketed today one can name Humira, Opdivo, Rituxan, Avastin, Remicade, Soliris, Lucentis, Herceptin, and Stelara.
In-demand research report “Monoclonal Antibodies - Global Trends in the Competitive, Technological and R&D Landscape” drawn up by CBR Pharma Insights offers a comprehensive assessment of the therapeutic mAbs domain.
It reviews both the pipeline and market shares of mAbs across a range of therapy areas. The study evaluates the R&D, clinical, commercial and competitive scenario of mAbs, and provides an assessment of essential developments in production and development, limelighting the strategies to stand up against challenges associated with the usage of mAbs in humans. Additionally, the report offers a highly granular categorisation of companies developing mAbs.
Reasons to Buy:
- Comprehend the current status of the area of therapeutic mAbs, and the relative commercial and clinical success of the marketed products today.
- Thoroughly assess the pipeline for mAbs broken down by therapy domain, type of mAb, and development stage; and across the 4 most active mAb therapy areas: oncology, contagious illnesses, immunology and CNS disorders.
- Get wise of the present-day competitive scene, with a granular breakdown of the firms actively involved in the mAb pipeline; Know the degree of involvement of pharma giants, and the extent to which mAbs fit into the respective companies’ portfolios.
More in-demand studies by CBR Pharma Insights can be found at its page.